Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial

Overview of attention for article published in The Journal of Headache and Pain, April 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 41 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,344 followers.

RT @EHF_Official: Monthly and quarterly fremanezumab significantly reduced the monthly average number of migraine days versus placebo in mi…

18 Apr 2021

Reply Repost Favourite

Monthly and quarterly fremanezumab significantly reduced the monthly average number of migraine days versus placebo in migraine patients with documented inadequate response to 2 to 4 migraine preventive medication classes. https://t.co/SQJ1SjG7Ek #migrain

18 Apr 2021

Reply Repost Favourite

Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial https://t.co/cnJG263PZl

17 Apr 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.